Despite a challenging 2024 for Boston’s life sciences market—marked by softening fundamentals and an oversupply of lab ...

Vertex Pharmaceuticals earned well-deserved kudos after Dr. Paul Negulescu snagged the 2025 Canada Gairdner International ...

PrimeXBT, a trusted and globally recognized broker, has upgraded its Referral Program, allowing clients to send free gifts of up to $100 in rewards to friends while earning a 20% commission on their ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex Pharmaceuticals has been the apple of investors' search engines, but its recent stock dip of 3.3% might have folks ...

The stock's rise snapped a three-day losing streak.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...